ReviewFrontiers in pharmacology2019
A Pharmacological Overview of Alpinumisoflavone, a Natural Prenylated Isoflavonoid.
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Bioactive Natural Products Targeting Androgen Receptor Signaling in Prostate Cancer: A Systematic Review.Cancers · 2026Review
- Dichloromethane fraction from Ficus hispida L.f. fruit extract suppresses lung cancer through cell cycle arrest and TNF-induced apoptosis.American journal of cancer research · 2026Article
- Incredible use of plant-derived bioactives as anticancer agents.RSC advances · 2025Review
- Alpinumisoflavone ameliorates experimental acute reflux esophagitis in rats via regulation of inflammatory pathway.Acta cirurgica brasileira · 2025Article
- Protective effects of alpinumisoflavone against streptozotocin-induced gestational diabetes mellitus in female rats: mechanistic insights and therapeutic potential.Acta cirurgica brasileira · 2025Article
- Enhanced Therapeutic Potential of Liposome-Coated Bushen Jianpi Recipe for Hepatocellular Carcinoma.Current drug delivery · 2025Article
- Roles of 4'-International journal of molecular sciences · 2024Article
- Targeting oxidative stress with natural products: A novel strategy for esophageal cancer therapy.World journal of gastrointestinal oncology · 2024Review
- Alpinumisoflavone Activates Disruption of Calcium Homeostasis, Mitochondria and Autophagosome to Suppress Development of Endometriosis.Antioxidants (Basel, Switzerland) · 2023Article
- The role of NLRP3 inflammasome in hepatocellular carcinoma.Frontiers in pharmacology · 2023Review
- Alpinumisoflavone against cancer pro-angiogenic targets: In silico, In vitro, and In ovo evaluation.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Article
- Alpinumisoflavone Exhibits the Therapeutic Effect on Prostate Cancer Cells by Repressing AR and Co-Targeting FASN- and HMGCR-Mediated Lipid and Cholesterol Biosynthesis.Life (Basel, Switzerland) · 2022Article
- Rare prenylated isoflavonoids from the young twigs ofRSC advances · 2022Article
- Alpinumisoflavone Impairs Mitochondrial Respiration via Oxidative Stress and MAPK/PI3K Regulation in Hepatocellular Carcinoma Cells.Antioxidants (Basel, Switzerland) · 2022Article
- Review
- Identification of Anti-Proliferative Compounds fromMolecules (Basel, Switzerland) · 2022Article
- In Vitro Antioxidant and Anticancer Properties of VariousMolecules (Basel, Switzerland) · 2022Article
- Alpinumisoflavone Disrupts Endoplasmic Reticulum and Mitochondria Leading to Apoptosis in Human Ovarian Cancer.Pharmaceutics · 2022Article
- Dietary Phytochemicals Targeting Nrf2 to Enhance the Radiosensitivity of Cancer.Oxidative medicine and cellular longevity · 2022Review
- Metabolomic Profile and Cytotoxic Activity ofPlants (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last decade, several studies demonstrated that prenylation of flavonoids enhances various biological activities as compared to the respective nonprenylated compounds. In line with this, the natural prenylated isoflavonoid alpinumisoflavone (AIF) has been explored for a number of biological and pharmacological effects (therapeutic potential). In this review, we summarize the current information on health-promoting properties of AIF. Reported data evidenced that AIF has a multitherapeutic potential with antiosteoporotic, antioxidant and anti-inflammatory, antimicrobial, anticancer, estrogenic and antiestrogenic, antidiabetic, and neuroprotective properties. However, research on these aspects of AIF is not sufficient and needs to be reevaluated using more appropriate methods and methodology. Further series of studies are needed to confirm these pharmacological effects, and this review should lay the basis for the design of respective investigations. Overall, despite the drawbacks of studies recorded, AIF exhibits a potential as drug candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.